Skip to Main Content

In March, as waves of Covid-19 cases began surging across the U.S., biotech venture capitalist Robert Nelsen was “pissed off” about his prescient fear that new biotech treatments, even if they emerged, would not be able to be manufactured in sufficient amounts.

As usual, Nelsen’s rage resulted in a new company: Resilience, backed by $800 million from Nelsen’s ARCH Venture Partners, 8VC, and other sources, and aimed at transforming manufacturing. The company’s board includes a who’s who of former industry and government officials. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.